UMN will exclusively provide to its new partner a recombinant virus-like particle (VLP) antigen produced using baculovirus expression vector technology UMN has licensed for Asia from the US firm Protein Sciences. Daiichi Sankyo will carry out basic…
written on 17.02.2014